Treatment options for recurrent high-grade gliomas

Harjus S. Birk, Seunggu (Jude) Han, Nicholas A. Butowski

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.

Original languageEnglish (US)
Pages (from-to)61-70
Number of pages10
JournalCNS oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Glioma
Glioblastoma
Molecular Targeted Therapy
Therapeutics
Recurrence
Brain Neoplasms
Radiotherapy
Drug Therapy
Neoplasms

Keywords

  • glioblastoma
  • high-grade gliomas
  • overall survival
  • progression-free survival
  • recurrence treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment options for recurrent high-grade gliomas. / Birk, Harjus S.; Han, Seunggu (Jude); Butowski, Nicholas A.

In: CNS oncology, Vol. 6, No. 1, 01.01.2017, p. 61-70.

Research output: Contribution to journalReview article

Birk, Harjus S. ; Han, Seunggu (Jude) ; Butowski, Nicholas A. / Treatment options for recurrent high-grade gliomas. In: CNS oncology. 2017 ; Vol. 6, No. 1. pp. 61-70.
@article{95d76996506f4c369ebb847cbd768ab4,
title = "Treatment options for recurrent high-grade gliomas",
abstract = "High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.",
keywords = "glioblastoma, high-grade gliomas, overall survival, progression-free survival, recurrence treatment",
author = "Birk, {Harjus S.} and Han, {Seunggu (Jude)} and Butowski, {Nicholas A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.2217/cns-2016-0013",
language = "English (US)",
volume = "6",
pages = "61--70",
journal = "CNS oncology",
issn = "2045-0915",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Treatment options for recurrent high-grade gliomas

AU - Birk, Harjus S.

AU - Han, Seunggu (Jude)

AU - Butowski, Nicholas A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.

AB - High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.

KW - glioblastoma

KW - high-grade gliomas

KW - overall survival

KW - progression-free survival

KW - recurrence treatment

UR - http://www.scopus.com/inward/record.url?scp=85050579807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050579807&partnerID=8YFLogxK

U2 - 10.2217/cns-2016-0013

DO - 10.2217/cns-2016-0013

M3 - Review article

C2 - 28001091

AN - SCOPUS:85050579807

VL - 6

SP - 61

EP - 70

JO - CNS oncology

JF - CNS oncology

SN - 2045-0915

IS - 1

ER -